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ABSTRACT 
 
In the United States alone, hundreds of millions of blood tests are performed annually, 
and a significant number of those tests are compromised due to hemolysis: e.g., 31% 
compromised in emergency rooms (inpatient) and 10% at blood banks, clinics, and other 
outpatient venues. Currently there is no way to reliably detect hemolysis without plasma 
separation. As a result, significant delays ensue, potentially negatively affecting patient diagnosis 
and treatment. In addition to in vitro hemolysis, which compromises the quality of blood tests, 
hemolysis can also occur in vivo. The in vivo occurrence of hemolysis is an indication of life-
threatening complications. Being able to detect early signs of in vivo hemolysis would 
significantly improve outcomes for many patients, including pregnant women affected by 
HELLP (Hemolysis, Elevated Liver Enzymes, Low Platelet counts) syndrome. Therefore, there 
is a critical need to be able to detect hemolysis near the patient, immediately following the 
collecting of blood sample.  
The goal of this research is to provide an alternative to the traditional testing of blood 
samples, which requires large volumes of blood, centrifugation, and bulky instrumentation. The 
proposed alternative hemolysis detection system is a simple miniature setup that produces test 
results in minutes. This miniature, near-patient sensor would improve patients’ diagnosis, 
treatments, general satisfaction, and overall experience. The potential reduction of healthcare 
costs associated with hemolysis would be another significant benefit. 
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The technology demonstrated in this dissertation is based on a novel combination of 
microfluidics, spectroscopy, and optical-fiber sensing. The microfluidics provide the capability 
to handle small volumes of liquid and to filter particles from solution. Novel membrane 
fabrication and modular integration provides the means to characterize and culture the captured 
particles. Spectroscopy and optical fibers provide the means to characterize the filtrate. These 
capabilities can be used for not only the detection of hemolysis but also other biomedical 
applications. . 
 The first step in detecting hemolysis is to separate blood cells and other unwanted 
particulates from the plasma needed for optical analysis of concentration of hemoglobin. To that 
end, we focused initially on the problem of particle separation—specifically, within a 
microfabricated chamber with a custom-designed transparent membrane. To create a miniature 
microfluidic system capable of processing microliter blood samples, microelectromechanical 
systems (MEMS) fabrication techniques were required. The fabrication process included steps 
such as low-stress vapor deposition, photolithography, plasma, and wet etching. The resulting 
microdevice proved capable of filtering a variety of biological test fluids, including human lung 
fibroblast cancer cells from medium. The transparent membrane also allows for spectroscopic 
studies in broader applications, such as spectroscopic analysis or culturing of the cells retained 
on the filter. These capabilities were demonstrated using microbeads and cancer cells in solution.  
Optical techniques are used to analyze the separated blood plasma for concentration of 
hemoglobin. To integrate spectroscopic capabilities with the above microfluidics system, an 
optical fiber–based miniature probe was attached to the microfabricated chamber.  As proof of 
concept, this system was tested in an application that required the measurement of 
physiologically relevant concentrations of cobalamin (vitamin B12). This application was used to 
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address human error in drug administration showing measurements of cobalamin concentration 
as an example drug that can be monitored. The clinical means range of concentrations is from 1 
µg/ml to 1000 µg/ml.  The achieved results showed measurements of concentrations between 1 
µg /mL to 5 mg/mL to monitor the physiological range and potential overdose in microliter of 
volume. 
This device has potential for numerous applications, ranging from single cell 
spectroscopy to measurements of glucose concentrations. 
This integrated system was then applied to the detection of hemolysis. The complete 
system conducts optofluidic spectroscopy with the optical fiber probe connected to the 
microfabricated chamber, which locally filters out blood cells, and reliably determine amount of 
free hemoglobin with the need for centrifuging. The utility of the device was demonstrated by its 
accurate measurement of hemoglobin concentrations in blood plasma. 
Finally, to apply the concept of the detection system to clinical condition with a reliable, 
and low-cost system, especially useful for developing countries, a smartphone-based technology, 
is proposed.  This technology delivers ultra-fast results for the detection of early signs of HELLP 
syndrome and preeclampsia with the goal to decrease mortality and morbidity.  The smartphone-
based diagnostics is low cost, high speed of operation together with high accuracy.  Detection of 
1 mg/dL of free hemoglobin was achieved which is comparable to gold standard assay which are 
time consuming, difficult to operate and expensive.  
This technology, in summary, integrates microfluidics with microfiltration and 
spectroscopic technology to conveniently separate and characterize blood plasma. The device 
can also provide important information about other complex biological samples. These 
measurements require only very small sample volumes. 
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CHAPTER 1: INTRODUCTION 
 
1.1  Motivation 
Prenatal conditions are the fourth leading cause of death in developing nations and also 
pose significant health risks in countries with high income [1]. Globally, preeclampsia and other 
hypertensive disorders of pregnancy are a leading cause of maternal and infant illness and death. 
By conservative estimates, these disorders are responsible for 76,000 maternal deaths and 
500,000 infant deaths each year [2]. Preeclampsia can rapidly escalate to a dangerous 
complication known as HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome. 
According to the Preeclampsia Foundation [2], the maternal mortality rate of HELLP syndrome 
has been reported to be as high as 25%. Overall perinatal mortality from HELLP Syndrome 
(stillbirth plus neonatal death) ranges from 7.7 to 60%. Among pregnant women in the United 
States, 5 to 8% develop preeclampsia. Clinical studies estimated that 15% of those women will 
develop evidence of HELLP syndrome. This means that as many as 48,000 women per year will 
develop HELLP syndrome in the United States. 
HELLP syndrome can be difficult to diagnose, especially in the absence of protein in the 
urine and high blood pressure. Its symptoms are sometimes mistaken for gastritis, flu, acute 
hepatitis, gall bladder disease, or other conditions. Late diagnosis results in much higher 
mortality and morbidity. One of the important indicators of HELLP syndrome is in vivo 
hemolysis (disruption of red blood cells and release of hemoglobin into blood plasma). Due to 
the very high speed of disease progression, delays related to blood testing increase risk for the 
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mother and the baby. A patient’s condition can severely deteriorate in just three hours, while 
many tests confirming diagnosis of HELLP syndrome also take several hours. Therefore, there is 
a need for new technologies that can confirm HELLP syndrome near patient, in minutes to 
address delays that can be detrimental. Here we propose and demonstrate a new technology for 
the detection of hemolysis, a key diagnostic symptom of HELLP syndrome. This dissertation 
aims to develop an important step toward early detection of hemolysis, with the goal of being 
able to confirm the diagnosis while there is still time to save the mother and the baby. 
1.2  Research Approach 
The new high-speed technology for the detection of hemolysis is based on optofludic 
spectroscopy. In particular, we work on absorption spectroscopy combined with microfiltration, 
with a focus on applications related to studies of different types of biological samples.  The 
custom-designed and fabricated microfilters enable the effective capturing of cells that can be 
isolated from blood and further studied under a microscope. Absorption spectroscopy integrated 
on an optical fiber platform is used for material characterization. This optofluidic technology, 
with its miniaturized optical and microfluidic sub-systems, supports not only real-time, label-free 
measurements, but also allows for analysis of very small sample volumes. The combination 
gives high precision results, flexibility and allows for insight into the biochemistry of blood and 
other biological samples.  
Because the specific application of this optofluidic platform is hemolysis assessment, 
filtering out blood cells, and measurement concentration of hemoglobin in plasma is required. 
The filtered cells can be next studied under a microscope in both upright and inverted 
configurations, since the micro-filter is a thin transparent membrane. In addition to imaging the 
captured cells on the microfiltering chip, this cutting-edge device provides an opportunity to 
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culture cells (e.g., circulating tumor cells) for further studies on the same chip. Therefore, this 
work provides a number of innovations: new architecture for optofluidic spectroscopy integrated 
on an optical fiber platform, a new method of hemolysis detection, and also a new multi-
functional filter that can also serve as an imaging and culturing substrate. 
1.3   Research Objectives 
The objective of this dissertation is to develop a new optofluidic platform that can rapidly 
quantify the level of hemoglobin in blood plasma. The research requires development of a new 
miniature spectroscopic system, a new microfluidic system for blood filtration, and a unique 
integration of the microfluidic component with an optical fiber. The complete system can be 
applied to a number of important applications in addition to hemolysis detection. 
The goal of this research is to contribute to the knowledge of science in the field of 
optofluidics and sensing by publishing in reputable peer-reviewed journals, and presenting in 
both national and international conferences. 
1.4   Dissertation Outline 
This thesis will present a new optofluidic system that combines spectroscopy with 
microfluidics. Some of the results were obtained in collaboration with other members of the USF 
Innovative Biomedical Instruments and Systems (IBIS) Laboratory.  
Chapter 2 of the dissertation introduces the state of the art and describes prior research 
related to hemolysis detection.   
Chapter 3 demonstrates the design, fabrication, and testing of a novel removable 
microfilter membrane that can filter cells or particles from biological samples. Additionally, 
there is experimental demonstration that the same removable microfilter can be used for further 
study of the captured cells under microscope and even for culturing. 
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Chapter 4 presents a new optofluidic spectroscopic device and its application towards 
elimination of human error in drug administration. This work has been published in the journal 
Sensing and Bio-Sensing Research. 
In Chapter 5, further optimization of the optofluidic system for better detection of 
hemoglobin is addressed and then experimental detection of hemolysis demonstrated. 
Chapter 6 present the application of optical sensing on a smartphone device.  This 
platform allows developing countries or low resource areas to have a relieable, accurate, and 
low-cost detection tool for preeclampsia and HELLP syndrome.   
Chapter 7 concludes my dissertation with an overall impact of hemolysis and the how the 
use of my research can reduce mortality and morbidity due to pregnancy complication.  Also a 
short summary of future work and other clinical applications the presented platform can be 
addressed.  
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CHAPTER 2:  BACKGROUND 
 
2.1 Hemolysis  
There are two types of hemolysis: in vitro and in vivo, both which negatively impacts the 
healthcare [3].  Additionally, millions of dollars are spent each year due to the inability to 
promptly detect hemolysis.  World-wide in vitro hemolysis affects the quality of blood testing in 
clinical settings, including hospitals, clinics, and blood banks [4].  Furthermore, presence of in 
vitro hemolysis results in test inconsistency, and eventually, negatively influencing diagnostics 
and treatment.   
In the case of in vivo hemolysis, early detection is critical for saving patient’s life.  This 
life-threating condition has devastating consequences for pregnant women suffering from 
hypertensive complications of pregnancies (HCP).  Globally, HCP are among leading cause of 
maternal death, and preeclampsia is one of the most frequently observed HCP.  In vivo hemolysis 
is a key symptom for one of complications of pregnancy – preeclampsia [5].  
Currently, hemolysis detection in whole blood is impossible. First, blood plasma has to 
be separated, and then the level of hemoglobin is determined based on ‘redness’ of the sample 
via visual comparison to a color chart.  While this method may have been used for a long time, it 
fails to effectively assess level of hemolysis at low levels of hemoglobin concentrations.  It is 
important to note that detection of hemolysis at low level of hemoglobin is very important for a 
number of biomedical applications, including diagnosis and monitoring of several diseases. 
Furthermore, the traditional approach to hemolysis identification has other important drawbacks 
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besides its low accuracy.  Large volumes of blood (measured in milliliters) are needed, in order 
to separate plasma using centrifuging method. . Though traditional analytical methods can also 
be used to detect hemolysis (e.g. ELISA), often reagents interfere with the measurements, which 
also results in inconsistency of hemolysis detection [6, 7]. Additionally, using ELISA for pre-
processing of each blood sample would greatly increase cost of blood testing, and thus not 
feasible in developing countries and income stricken areas.  Therefore, due to all these 
limitations of the visual assessment there is a need for an automatic method to detect hemolysis. 
There are numerous benefits that the automated device can bring. First, it can really 
improve accuracy of in vitro hemolysis detection. This can help to identify unusable samples and 
thus improve diagnostics. It will have an important impact on healthcare and economy [3]. 
Second, it can help with detection of in-vivo hemolysis present in case of HELLP syndrome. 
The rest of this chapter will focus on research related to hemolysis, how it affects 
different facets of healthcare, and how our technology can contribute to an effective detection of 
hemolysis.  
2.2 In-vivo Hemolysis  
2.2.1 Hemolysis and Hypertensive Disorder of Pregnancy 
In-vivo hemolysis, can be linked insufficient production of red blood cells (RBCs). RBCs 
do not survive over their normal life span (~ 120 days). Due to certain mechanism the RBCs 
undertake, they are destroyed before their life span. Therefore, the body relies on the bone 
marrow to replenish the cells as fast as they are destroyed. Unfortunately, when the bone marrow 
is unable to timely replenish the cells, the patient then has low number of RBCs. This condition 
is known as a hemolytic anemia. Hemolytic anemia can be provoked by intravascular destruction 
of RBCs, which is observed for such conditions as sickle cell disease and HELLP syndrome [8, 
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9] [10-12]. This conditions due to hemolysis results in high morbidity in high income countries 
and high mortality in low income countries. In industrialized countries, number of deaths from 
preeclampsia and other pregnancy-related complications per number of live births is between 1 
in 4000 and 1 in 10,000. However, in low income countries, this ratio is between 1 in 15 and 1 in 
50 [13].   
The sudden escalation of preeclampsia to eclampsia/HELLP syndrome in pregnant 
women, adds sufficiently to the rate of mortality. The progression from mild pre-eclampsia to 
severe pre-eclampsia can occur within a couple hours, without much clinical warning. Number 
of studies demonstrated that the level of free hemoglobin in plasma starts increasing in early pre-
eclampsia, and then can reach very high level together with progression to HELLP syndrome 
[14, 15]. Unfortunately, the detection of in vivo hemolysis has increasing delays associated with 
testing, and often confirmed too late.   
2.2.2 Clinical Diagnostics and Management of Preeclampsia/HELLP Syndrome 
The diagnosis of pre-eclampsia/HELLP syndrome is made in the hospital through 
analysis of serial blood pressure measurements, detection of proteinuria, as well as several labs 
including aspartate transaminase (AST), alanine transaminase (ALT) lactate dehydrogenase 
(LDH), uric acid, hemoglobin/hematocrit, platelet count and a coagulation profile (PT/PTT, 
fibrinogen and D dimer). Patients with HELLP syndrome have a combination of elevated 
enzyme levels, elevated uric acid, diminished platelet count, and proteinuria.  This condition is 
very severe, and possibly coagulopathy. The hemoglobin/hematocrit can be elevated due to 
hemo-concentration, or it can be reduced if the patient is coagulopathic.  
When a patient has mild pre-eclampsia and is remote from term, it’s important to test 
periodically if the patient is deteriorating. Patients might be given magnesium sulfate as 
8 
 
prophylaxis of eclampsia and a course of corticosteroids to enhance fetal lung maturation. Once 
the diagnosis of severe pre-eclampsia and/or HELLP Syndrome is confirmed, the recommended 
management is the delivery of the baby.  If the patient develops the associated coagulopathy, she 
might require transfusion of blood and/or blood products for reversal of this disorder.  It is 
important to note that the use of corticosteroids to improve the maternal condition is 
controversial.  Therefore, it’s also important to diagnose these conditions earlier to avoid 
controversial approach. 
2.3 In-vitro Hemolysis 
2.3.1 Overview of In-vitro Hemolysis  
Currently, clinicians collect, handle, and store blood specimen before sending them to 
laboratory. In order to ensure appropriate quality of the samples, avoiding hemolysis, there are a 
number of practices that has been used.  It’s been suggested to use straight needles venipuncture, 
vacuum tube, and antecubital fossa vs. more distal site [16]. Despite all this effort, sample 
contamination still remains a concern.  This is especially true in emergency departments, which 
has greater than 30% rate of hemolysis [17].  Also, 60% of all rejected clinical blood specimen 
were rejected due to hemolysis, according to Soderberg et al [18].   Other types of sample 
contamination include general collection errors and serum preparation errors.   
A study showed that 91% of personnel in blood testing facilities were aware of 
hemolysis, but only 58% of the 91% were monitoring the hemolysis level in their samples 
systematically and were aware of the numbers, and origin of hemolyzed samples they receive in 
their laboratory [19].  In a different study, of 10,709,701 samples from 453 laboratories, 37,208 
samples were rejected due to hemolysis [20] and, therefore, multiple samples had to be collected 
from patients.  For some of patients 3-5 blood samples were collected [19, 21].   
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2.3.2 Methods Used for In-vitro Hemolysis Detection 
Currently, visual assessment method is used for hemolysis detection in most clinical 
laboratories. The color of centrifuged plasma is assessed for hemolysis either with or without 
reference guide, using hemolysis index (HI) [18].  The level of free hemoglobin is correlated to 
HI and reported as one of the following: no hemolysis, slightly hemolyzed (pink tinged), 
moderately hemolyzed (red), grossly hemolysis (dark red), (Figure 2.1).  This method is very 
subjective and not standardized [22].  Different laboratories reported different detection limits 
for HI, i.e. HI >/=  20 or HI >/= 15, which can both represent “No hemolysis” [18, 23].  It has 
been showed that many hemolyzed samples assessed without reference guide were categorized 
incorrectly comparing to the assessment using automatic systems [4, 24].  Several automatic 
methods are used to assess hemolysis - ELISA and spectrophotometry methods such as Harboe 
method [25]. The spectroscopic methods are based on various wavelengths. Harboe method is 
based on near-UV spectropohotmetry, others use Soret band for a more intense signal than 
visible absorption band [26-28].  They all need several milliliters of blood, require plasma 
separation and takes time to complete, thus would not work for rapid quality assessment based 
on just a drop of blood. 
The amount of free hemoglobin for healthy individuals is 0.001 – 0.004 g/dL (1- 4 
mg/dL) [19].  For in vivo hemolysis which occur in pregnancy complications, total hemoglobin 
in whole blood of a pregnant woman is usually within the ranges from 11.6-15 g/dL (11,600 – 
15,000 mg/dL) as showed in table 1.  The upper limit for free hemoglobin in blood plasma of a 
healthy person is 0.004 g/dL (4 mg/dL). However, hemoglobin concentration that can be defined 
visually is greater than 30-50 g/dL [10], figure 2.1. Additionally, elevated concentration of other 
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blood component such as bilirubin complicates visual detection and even some analytical assays 
[29].   
Since upper level of hemolysis in pregnancy complications can be as high as 3 g/dL and 
above, there is a challenge in designing a system that has a dynamic range of three orders of 
magnitude [19].   
Table 1: Hemoglobin concentration in whole blood of women 
 
  
 
Figure 2.1 Current visual detection method for hemolyzed samples.  From left to right, ranks 
pure to grossly hemolyzed samples, with free hemoglobin in plasma ranging from less than 0.5 
g/dL to greater than 30g/dL [16]. 
 
 
In summary, traditional visual assessment of hemolysis is unreliable, while available 
automatic measurements require extensive time and prohibitively expensive. Therefore, there is a 
great need in an accurate, fully automatic hemolysis assessment tool that can precisely measure 
free plasma hemoglobin for both in vivo and in vitro hemolysis.  
 
 
   Units Nonpregnant Female First Trimester Second Trimester Third Trimester 
g/dL 12 -15.8 11.6 - 13.9 9.7 - 14.8 9.5 -15 
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2.4  Alternative Approaches to Sensing 
Recent advancement in technology has improved many types of biomedical sensors.  
Optical detection methods such as fluorescence, absorption and Raman can be used for analysis 
of biomedical samples using light. Different electrochemical, optical, and thermometric methods 
can be used to analyze biochemistry with high sensitivity and specificity [30].  Additionally 
different Point-of-care testing and Lab-on-a-chip (LOC) technologies have more applications in 
the biological and medical fields. Below, focus is based on analyzing existing technologies and 
using these concept to design a new technology for hemolysis detection. 
2.4.1 Spectroscopy 
Optical absorption spectroscopy analyzes materials by measuring the amount of light 
absorbed in relation to the light frequency or wavelength.  It is widely used in chemistry, biology 
and medicine and has high sensitivity, and specificity [30-32].  An additional benefit of 
spectroscopy includes real-time analysis on complex fluids without the need for preanalytical 
processing or large sample volumes. It is especially important for medical applications, since 
blood testing instruments have to be compact, operate with small blood volume (microliters), and 
still be precisely accurate. Furthermore, spectroscopy can be integrated with other passive and 
active components, such as filters, mixers, on a single microfluidic chip. 
One applications of spectroscopy for biomedical applications is glucose measurement. 
Many researchers are trying to find a good alternative to traditional finger pricking.  A semi-
invasive near infrared (NIR) glucose monitoring based on absorption spectroscopy with a 
microfluidic chip showed detection limit of the measurements to be 20 mg/dL [33]. However, 
Anas et al demonstrated a non-invasive near-infrared glucose measurements [34].  Furthermore, 
since a pressing need for compressive analysis has led to demonstration of comprehensive 
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analysis of total biochemical composition of plasma and in blood with infrared spectroscopy was 
used to distinguish between cancer and non-cancer patients [35]. 
For application on detection of hemolysis, concentration of hemoglobin can be extracted 
from spectroscopic measurements using Beer-Lambert Law (1), in which absorbance is directly 
proportional to the path length, and concentration of an absorptive component.   
A = Ɛlc, where A is the total absorbance, Ɛ is the molar absorptivity, l is the path length, 
and C, concentration. Alternatively, transmission T can be measured with respect to the same 
parameters.  
T =
I
Io
= e−αl = e−ɛlc                                             Equation 1 
where, T = Transmission of light through the system; I and I0 are initial and transmitted light 
intensity.   
Since different molecules absorb in different parts of the optical spectrum, this absorption 
“fingerprint” can be used to identify components and measure their concentration. Base on this 
principle, a device was designed, that can determine the concentration of hemoglobin present in 
blood plasma, real-time.  
2.4.2  Optical Fibers 
Optical spectroscopy can be conducted on large instruments, but currently there is a lot of 
interest in its miniaturization and integration on highly compact optical fiber platform. In 
general, optical fiber are great for miniature sensing because they are lightweight, have low 
power consumption, and high bandwidth [36], and can be used in a dangerous environment [37, 
38].  Other applications of optical fibers range from networks and communications [38-41] to 
chemical and biomedical sensing.  In particular, in sensing, optical fibers can be used to measure 
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temperature, pressure and other physical parameters [36], in addition to many chemical and 
biological substances [42].   
There are many different kinds of optical fibers made from glasses and plastics and 
having different core/cladding configurations. 
Some of them are optimized for a specific wavelength, while others support broadband 
signal propagation. If fiber diameter is less than 250 µm, it can be inserted into medical 
instruments, such as catheters, IV bags, or needles for highly localized measurements.  
2.4.3 Microfluidics and Optofluidics 
While optical fibers allow conducting very sensitive measurements on small samples, 
handling these small volumes of fluid requires use of microfluidics [43]. The integration of 
microfluidics with optical fibers enables creating a miniaturized platform for quantitative 
analysis of many biological fluids including blood, urine, and saliva [44, 45]. The field that 
allows this integration is called optofluidics, and it has important applications in telemedicine 
and point of care testing. Benefits of optofluidics include cost reduction and improved efficacy.  
Additionally, it can help bringing affordable, rapid and accurate medical diagnostics to lower 
income countries [46-48].   
Currently, because of the lack of infrastructure, and low resources, many patients suffer 
from the lack of adequate diagnostics, which further results in lack of treatment.  Improvement is 
needed to combat such diseases as HIV/AIDs, malaria, Ebola and many others.  The 2014, 
United Nations report showed an increase of lives saved through malaria interventions (3 million 
young children between 2000 and 2012), 22 million lives saved with tuberculosis treatment, and 
9.5 million people received antiretroviral medicine [49].  Though this incredible improvement 
has been made, almost 600 children still die every day of AIDs-related causes, and a record high 
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of estimated 35.3 million people still live with HIV worldwide [49].  Furthermore, 210 maternal 
death per 100,000 live births were recorded in 2013, this number indicate a decrease from last 
recording of 380 deaths, however, the report stated that much more was needed in this area to 
provide adequate care for pregnant women and their babies [49].   
2.4.4  Mobile Medicine 
Another way to conduct low cost sensing in developing countries is through the use of 
mobile phones. Seven billion mobile phone subscriptions were reported in the 2014 United 
Nation report. This means that even in a very low resource environment the mobile phones 
become available, and thus can be used for healthcare applications. Cell phone imaging can be 
seen as a grandchild of optical spectroscopy which has been used for quantitative and specific 
diagnosis of many disease [46].  There have been many advances in cell phone imaging and 
analysis [50, 51]. For example, Ozcan Lab developed a platform for mobile phone based 
microscopy and flow cytometry [51, 52].  Other advances of mobile phone based images include 
super-resolution algorithm [53, 54] allowing to conduct sample imaging with the sub-pixel 
resolution limits [55]. Furthermore, researchers have demonstrated mobile phone colorimetric 
assays.  A cellphone-based urine analysis platform sensing marker PCADM-1 for prostate cancer 
diagnosis was developed by GENTAG, Inc and MacroArray Technologies, LLC [56].  Another 
system was created for E. coli detection. It used anti-E.coli antibody-functionalized arrays and a 
quantum dot (QD) immunoassay [57]. Additionally, this system used battery-powered ultra-
violet LEDs that allowed uniform excitation of the labeled E.coli. 
2.4.5 Point-of-Care Testing and Lab-on-a-Chip 
 One of important trends in contemporary healthcare is that it evolves from the standard 
laboratory processing using large instruments, large samples and large volumes of expensive 
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reagents to the use of point-of-care devices and lab-on-chip.  It helps to address sanitization of 
device in clinical setting, improves automation and operation speed, and decreases sample 
volume [58, 59].  
The POC and LOC platform can be applied to a number of studies in blood. For pregnant 
women who developed preeclampsia, the level of hemoglobin in their blood is an important 
indicator of the disease progression.  Other important parameters of blood are uric acid, related 
to the kidney health, number of platelet, hematocrit, and percentage of red blood cells (RBCs) 
with abnormal shape and functionality.  For instance, a label-free optofluidic POC device 
demonstrated detection of cells distribution based on size and stiffness with high sensitivity 
using encoded forward light scattering signal [59].  Compare to the typical blood volume needed 
for blood analysis, this compact, inexpensive system needed ~5 µL of human blood. 
 In this dissertation we integrate together spectroscopy and microfluidics on optical fiber 
platform and demonstrate several important POC applications of this new technology.  
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CHAPTER 3: A NEW APPROACH TO MICROFLUIDIC FILTRATION: MODULAR 
FILTERS THAT CAN BE ATTACHED AND REMOVED FROM MICROFLUIDIC 
CHIP 
 
3.1        Introduction 
  The traditional approach to microfluidics is based on monolithic integration of 
multiple components on a single chip [60]. This approach allows for the simultaneous 
fabrication of multiple components including, but not limited to, microfluidic channels, 
filters, and sensors, thus enabling many functionalities [61, 62]. However, the monolithic 
integration of a microchip requires that all of the functional components comprising the 
microfluidic circuit are fixed at the time of fabrication. In order to change the parameters 
of the microfluidic filter or the characteristics of a sensor, the whole functional layer must 
be changed, new photolithographic masks must be created, and all fabrication steps must 
be repeated. 
  We propose the fabrication of some select microfluidic circuit components on 
separate microfluidic chips and seamlessly connecting them with the main circuit. This 
introduces a completely new level of flexibility to microfluidics and allows for custom 
integration with different kinds of sensors, filters, or other microfluidic components. In 
this paper, we focus on microscale filters because they are not only very important for the 
field of microfluidics, but frequently cause problems for the whole system operation.  The 
ability to exchange a clogged microfluidic filter for a new one without the need to throw 
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away the whole microfluidic-chip would increase the economy and efficiency of future 
microfluidics. Furthermore, filtering on the micro-scale is needed for a broad range of 
applications, such as capturing circulating tumor cells, separating blood cells from 
plasma, and collecting high concentrations of food pathogens or other small-sized 
particles from complex solutions or biological samples [63-68]. 
3.1.1  Current Approaches to Filtering of Microparticles 
  Traditionally, the separation of microscale particles from a complex liquid sample 
requires either centrifugation [62], mechanical millilitre-scale filtering using syringes 
[69], vacuum filter units [70], attachable filter membranes [71], or microfluidic filtration 
[72-74].  Centrifugation is widely used for biomedical applications, such as the separation 
of blood cells from plasma. It works only on relatively large sample volumes, measured 
in milliliters, while many applications, (e.g., capturing circulating tumor cells) require 
microfiltration [75-78]. 
 Mechanical filtration is widely used for laboratory sample pre-processing; tissue culture; 
biological fluids; fixation buffers; particle removal and clarification. This strategy is most 
effective for work on large scales or for high volumes and pressures [79-81].  The filtering 
membranes used for this approach can be made from a variety of materials, such as regenerated 
cellulose, polyethersulfone, surfactant-free cellulose acetate, nylon, or "PTFE" fluourocarbon 
resin. Yet this is not an effective approach for work that requires small volumes or for on-chip 
applications [82]. 
Processing of small fluid samples requires the use of microfluidics. One approach 
is to use size-restrictive filtration based on micro-pillars and micro-channels [83-86]. 
However, fluid flow through these structures requires high pressure and frequently results in 
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damage to the filters or degradation of biological samples [77] through induced blood hemolysis 
and cell fragmentation. 
3.1.2 Sample Processing After Microfiltration 
 While there are multiple microfluidic filters [65-68, 75-77], their main purpose is 
typically limited to filtering out unneeded particles or cells. However, it is frequently necessary 
for on-chip micro-filtration to be followed by microscopic or spectroscopic analysis of captured 
microscale objects, or by ﬂuorescence in situ hybridization (FISH) [78, 88, 89]. Previously, this 
analysis has been completed after filtration using specialized instruments [90-92]. The 
inconvenience and cost of the aforementioned approach has created a need to simplify the 
extraction of captured objects before conducting analysis. This can be done using removable 
building blocks for microfluidics that can be easily inserted or extracted from the microfluidic 
circuit.  
3.1.3  Experimental Approach 
  Here we demonstrate a new, modular, microfluidic filter that can be attached to a 
microfluidic chip and later removed or exchanged for another filter. The filter is a thin 
porous transparent membrane with a pore size smaller than the particles being filtered 
[93]. It can easily be attached to microfluidic chips to capture particles; then be detached 
and used for particle analysis under a microscope or for spectroscopic studies [94].  Using 
a 1µm thick membrane instead of long microfluidic channels helps to significantly 
increase filtering area, decrease the pressure, and eliminate damage to the biological 
samples. Furthermore, if the accumulation of a large number of particles prevents 
microfluidic flow, the filter can be easily removed and exchanged for a new one. This 
modular configuration provides a simple, convenient tool for fast isolation and analysis of 
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cells, bacteria, and micro-particles. Additionally, this new technology can be used fora 
broad range of chemical, biomedical and safety applications. 
3.2 Materials and Methods 
3.2.1  Membrane Fabrication 
  The modular microfluidic filter captures particles using a porous membrane with a 
periodic array of holes shown in (Figure 3.1a). It was fabricated using the process flow 
shown in (Figure 3.2a-f). In order to enable the separation of a variety of particles from 
solution, numerous designs consisting of different pore sizes and configurations were 
fabricated on a single photolithographic mask. The pore sizes ranged from 1µm to 20µm 
in diameter, and each device was contained inside of a 5 mm square. 
  The detailed fabrication procedure used for processing was the following (Figure 
3.2). To begin, 1µm thick layers of silicon nitride were deposited on double-side polished 
wafers using the Nitride Tystar low pressure chemical vapour deposition (LPCVD) 
diffusion furnace at GATech MiRC facility; details of the LPCVD preparation process 
can be found here [89]. Next, photolithography was conducted using a chromium mask 
and AZ4620 photoresist; followed by silicon nitride etching in a PlasmaTherm reactive 
ion etcher and the removal of the residual photoresist. The backside of the same wafer 
was then photo lithographically patterned after careful alignment of the front and back 
structures [95]. 
  The next process step was silicon etching of the wafers in a heated solution of 
potassium hydroxide [94]. After this was completed, the micro-filtering membrane was 
released from the underlying silicon and a small chamber with a height equal to thickness 
of the wafer was formed. The backside of the chamber was patterned with a large circular 
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opening. The scanning electron microscope (SEM) image of the completed device is 
shown in (Figure 3.1). The small chamber together with the top and bottom membrane is 
shown in the image.  
  When fabrication was completed the devices were cleaned and diced using a 
dicing saw. After this, the hydrophilic properties of the membrane were tested to make 
sure that the fluid would run through the pores without the need to apply high pressure. 
Figure 3.3 shows that the contact angle for the water of water drop on the membrane was 
35.7 and that the membrane was hydrophilic. 
 
 
Figure 3.1 SEM image of a micro-fabricated filtering membrane. The large square is the 
membrane on top side of the wafer. It has a periodic array of holes through which we can 
see a smaller square which is a membrane on the bottom side of the wafer that has one 
circular hole in the middle. 
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Figure 3.2 Fabrication process for the transparent reconfigurable microstrainer. (a, b) Low stress 
silicon nitride is deposited on both sides of a double side polished wafer. (c, d) Photoresist is 
spin-coated; photolithography is used to pattern pores in the membrane followed by the etching 
through the nitride layer. (e) The wafer is flipped and the backside is patterned using 
photolithography and etching. (f) To complete the fabrication, KOH is used to release the 
structure. 
 
 
Figure 3.3 Water contact angle measured on the surface of the fabricated membrane  
3.2.2 Packaging and Integration 
  Here we propose two approaches towards packaging of the modular membrane. 
The integration of the filtering membrane into a microfluidic device requires the 
membrane to be encapsulated across micro-channels containing the solution to be filtered. 
The first approach is shown in Figure 3.4; in this method, the filtering membrane is still 
attached to the supporting piece of silicon substrate and is sandwiched between two 
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Polydimethylsiloxane (PDMS) adapters inserted between two glass slides (Figure 3.4 a-
d); The purpose of the PDMS adapters is to hold the membrane in place by touching only 
the supporting substrate, but not the membrane. Even though the membrane is very robust 
(after integration into the microfluidic system it can operate continuously for hours 
without breaking), the direct attachment to the membrane is challenging because it is very 
thin. The PDMS structure protects the membrane which allows for simple assembly and 
disassembly of the filter. Along with the adapters, glass slides are used to provide 
mechanical support and to facilitate integration with capillary tubes. To achieve this, a 
small opening is drilled into two glass slides in which thin capillary tubes are inserted. 
The complete device can then be connected to other microfluidic chips through these 
tubes. Figure 3.4 e-f demonstrates how this microfluidic filter would separate red blood 
cells from a blood sample and provide blood plasma as the filtrate. This application would 
be very beneficial for many diagnostic microfluidic chips that work well with blood 
plasma, but fail with whole blood. 
 Figure 3.5-a shows a variety of membranes with differing sizes and pore diameters 
all fabricated on a single 3-inch wafer. After the wafer is diced, an individual chip, with a 
selected membrane size, is inserted into the configuration described in Figure 3.4. Figure 
3.5 b shows the complete assembly that includes a membrane with 6µm pores Figure 3.5 
c. Figure 3.5 d) and e) show the second approach towards filter device assembly, where 
the micro-channels and the insertion chamber are moulded in PDMS. This second 
strategy simplifies the insertion and removal of the filtering membrane, yet, this comes 
with the cost of a slightly more difficult tubing attachment when compared to the first 
integration approach. Both methods work equally well, and the choice of one over the 
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other depends on the specific application of the filter and the consideration of future 
integration with the design of other microfluidic chips. 
 
Figure 3.4 3-Dimensional model of proposed integration of the filtering membrane into a 
microfluidic filter. The membrane is sandwiched between two protective PDMS adapters 
inserted between two glass slides (a-d). The proposed filtering of the whole blood sample 
is shown in (e-f). 
 
 
Figure 3.5 Integration of the membrane into a microfluidic filter. (a) A 3-inch silicon wafer with 
multiple microfabricated filtering membranes. (b) Membrane sandwiched between supporting 
glass slides with the tubes attached. (c) Close-up of the integrated membrane that has a periodic 
array of pores each one 6 µm in diameter. (d) and (e) show an alternative approach to integration, 
where the whole microfluidic structure including microfluidic channels is moulded in PDMS. 
The membrane is inserted across the channels. 
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3.3  Results and Discussions  
3.3.1  Microfluidic Filtration and Further Sample Processing  
  The microfluidic filter was tested with a variety of solutions (Figure 3.5) and it was 
demonstrated that the membrane can effectively separate particles from the filtrate. 
(Figure 3.5a) shows the filtration of a solution that consisted of a high concentration of 
dark brown microspheres in water. The brown fluid flows from the left, and after going 
through the membrane that is inserted perpendicular to the microfluidic channel, the fluid 
becomes clear (on the right). The fluid was pumped using peristaltic pump with a 
minimum flow rate of ~2µL/s working at the lowest setting. Microchannels were moulded 
in PDMS using very thin capillary tubes. The microfiltering membrane was inserted 
perpendicular to the channel for filtration and later extracted for analysis of the captured 
particles. Figure 3.6 b demonstrates that cells can be successfully captured using the same 
microfilter with a pore diameter smaller than the cells being used. The cells in this 
experiment are Human Lung Fibroblasts, IRM-90, from ATCC.  
 The filtering ability of the membrane depends on the size of the pores along with 
the size of the particles; when large particles are captured, smaller ones can still go 
through. (Figures 3.6 c and d) demonstrate 20 µm microbeads captured on a membrane 
with 10 µm pores. Figure 3.6 c is focused on microbeads, while Figure 3.6 d is focused on 
the membrane. Figures 3.6 e and f show that the particles that are smaller than the 
membrane pores can easily flow through the pores to the other side of the membrane. By 
focusing above and below the transparent membrane, particles can be observed on both 
sides. It is also demonstrated that focusing through the membrane produces an image of 
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almost identical quality when compared with directly observing the particles on top of the 
membrane. 
3.3.2  Filtration Operation 
  The design configuration of the circular opening (figure 3.1) enables the extraction 
of fluid medium from particles and cells. Yet, the filtration of particles of different sizes 
requires tight control of the change in pressure across the membrane to keep the larger 
particles from damaging the thin transparent silicon nitride membrane. To achieve this 
control is it necessary to know the volumetric flow rate, Q. Given in equation 1 below, Q 
is calculated knowing the diameter of the capillary D, the velocity of the fluid V, and the 
viscosity of the fluid, 𝛾, (for distilled water it is 0.894 × 10−3 𝑃𝑎. 𝑠.). 
𝑄 =
𝜋
4
𝐷2𝑉                                                       Equation 1 
The volumetric flow rate is related to the pressure across the membrane by the Hagen 
Poiseuille equation. 
∆𝑃 =
8𝛾𝐿𝑄
𝜋𝑟4
=  
128𝛾𝐿𝑄
𝜋𝐷4
                                       Equation 2 
where viscosity, 𝛾 and volumetric flow rate, Q are used along with channel length, L and 
channel diameter D. 
  It was observed that efficient particle separation, without damage to the membrane, 
was achieved when the V was measured as 1.79 × 10−3 𝑚/𝑠.  Based on this velocity, Q 
was calculated to be 2 𝜇𝐿/𝑠 and the pressure drop across the membrane while particles 
are filtered (Figure 3.6) was calculated as 2.70𝑃𝑎.    
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Figure 3.6 Demonstration of microfluidic filtration. (a) Filtration of concentrated particle 
solution. (b) Filtered Human Lung Fibroblasts cells. (c) and (d) show 20 µm microbeads 
captured on a membrane with 10 µm pores with a focus on beads (c) and the membrane (d). (e 
and f) are focused above and below the transparent membrane and show that small particles can 
go through the membrane. 
 
3.3.3  Biological Sample Integrity 
  In the next experiment, captured Human Lung Fibroblast cells were cultured directly 
on the microfiltering membrane in 10% FBS/1% antibiotic medium Figure 3.7. Figure 
3.7a demonstrates that the cells were successfully attached to the membrane and were 
able to grow. Figure 3.7b shows fluorescent image obtained using a LIVE/DEAD® Cell 
Viability Assay. In this figure the cells fluoresce with green light demonstrating that they 
are all alive. 
  For safety, all experiments with captured or cultured cells on the microfiltering 
membranes were completed in an aseptic environment. The membranes were cleaned 
with ethanol solution (70%); removing all chemical residues. Next, fibronectin was 
coated on the membrane to assist in the cell adhesion and mitosis.  For culturing, the 
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membrane was used without any further preparation steps; however for fluorescent 
imaging, cells were incubated in a 1:1 fresh medium mixed with fluorescence dyes.   
Figure 3.7 Microfiltering membrane with the Human Lung Fibroblasts cells grown on its 
surface. (a) Optical microscopy image of the membrane with the cells. (b) Green 
fluorescent images of cells demonstrating that all of them are alive. 
  
3.4   Conclusion 
  We have designed, fabricated, and tested innovative modular microfluidic filters 
that can be used as an exchangeable building block for the implementation of complex 
microfluidic circuits. Filtering and capturing of particles and cells from a number of fluids 
has been demonstrated; along with the ability to use the same filter for the analysis of the 
captured content. The thin transparent microfiltering membrane can be used for bright 
field and fluorescent microscopy and even for the culturing of captured cells. This device 
has a multitude of potential applications in microfluidics ranging from the capturing and 
analysis of the circulating tumor cells, to other industrial applications including food 
analysis, safety and security. 
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CHAPTER 4:  OPTOFLUIDIC SPECTROSCOPY INTEGRATED ON OPTICAL FIBER 
PLATFORM1 
 
4.1 Introduction 
The Institute of Medicine estimated that as many as 98,000 patients die each year due to 
preventable medical errors, making this the sixth leading cause of death in the United States, and 
claiming more lives than diabetes or Alzheimer disease [96].  Additionally, the expense of 
medical care necessitated because of medical errors, lost income, and disability, results in a total 
cost between $17 billion and $29 billion per year [97].  There are many potential sources of error 
in patient care, such as medical prescriptions, transcriptions, dispensing and administration of 
drugs, and monitoring patient’s responses.  However, among these, administration errors account 
for approximately 32% of morbidity and mortality cases in inpatient facilities [97].  Because of 
this, there is a pressing need to detect drug identity and concentration during administration, 
allowing for precise measurement of dosages, and preventing errors in real time before adverse 
effects take place.  
While monitoring of  specific medications such as antidepressants and anticoagulants are 
important for compliance and toxicity checks [98], there are many other pharmaceuticals that 
when wrongly administered will result in dangerous consequences [99]. Currently, several 
specialized assay based techniques have been used to monitor medication errors in specific 
therapeutic treatments, known as therapeutic drug monitoring (TDM) [98-101].  However, assay 
and label based detection systems such as immunoassays, electrochemical assays, and lateral-
                                                 
1 This chapter was previously published. Permission is included in Appendix A.  
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flow assays (LFAs) have several limitations that prevent them from being used for point-of-care 
sensing [102]. These techniques are time consuming, and require large volumes of analyte to 
achieve the needed sensitivity. Furthermore, drug assays use complicated electrochemical 
measurements, suffer from background interference in complex solutions and have poor thermal 
stability [103-109]. Currently there are no available technologies for detection of overdose or 
incorrect drugs during administration. 
There are many sensors that can work in almost real time and do not require use of 
reagents, but they typically measure refractive index and are based on ring-resonators [110-113], 
photonic-crystals [114-116], whispering gallery-mode [117-119], plasmonic structures [120] and 
other optical components, that without additional modifications do not provide enough 
specificity for differentiation between multiple drugs.  In addition, these techniques are prone to 
noise caused by any microscale particles present in the system and are very sensitive to small 
temperature changes.  
In general, traditional approaches to drug identification include color test [121], 
microscopic microcrystal analysis [122], thin layer chromatography [123], gas chromatography 
[124], mass spectroscopy [125], X-ray diffraction [126], and different types of spectroscopy that 
are most suitable for real time detection. By using traditional spectroscopic techniques (IR, Near-
IR, NMR, Raman) it has been shown that drug identity can be determined [127-130]. Once a 
drug has been identified using traditional spectroscopy, information regarding concentration may 
be obtained by quantifying absorption at a specific wavelength. Furthermore, spectroscopy using 
a single optical fiber is becoming a powerful approach for analysis of biological samples [131-
135]. 
30 
 
However, for complex systems such as biological fluids that contain a variety of free 
floating particles and cells, the effectiveness in determining a drugs concentration is significantly 
reduced due to scattering and interference by these objects.  As a result, additional reagents are 
required to amplify the spectral signatures of compounds of interest (e.g. biomarkers of a specific 
multiple diseases) [136-138].  Unfortunately, studies requiring reagents and labeling can only be 
performed in specialized laboratories, using large sample volumes, as well as extensive time for 
analysis ranging from several hours to multiple days.  Because of this, a reliable, reagent and 
label-free, detection method that can run in real-time by using a small sample volume would 
greatly benefit point-of care drug monitoring. 
To overcome these limitations we have proposed a new optofluidic platform that can be 
used to detect the concentration of drugs by absorption spectroscopy, free of noise from particles 
and cells, without prior sample pre-processing.  This device is small enough that it can be 
directly inserted to an IV bag or syringe, and continuously monitor drug concentration before or 
while the patient is being treated.  Additionally, this device can be mass-produced and requires 
relatively inexpensive materials.  
4.2 Materials and Methods 
4.2.1  Device Principles 
 The device was designed to be a compact probe, consisting of a miniature microfluidic 
chamber attached to the interface of an optical fiber (Figure 4.1).  The bottom of the microfluidic 
chamber consists of a porous membrane that allows fluids and chemical compounds to flow 
inside the device, while at the same time filtering out undesired particles. Furthermore, the 
porous membrane is coated with a reflective metal. Because of this coating, light will pass 
through the filtered fluid and reflect back once it reaches the membrane. The reflected light can 
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then be collected by the optical fiber for spectroscopic analysis of the filtered fluid. Based on the 
absorption of light by the fluid, the system can provide a conclusion if the drug dosage is correct. 
The top portion of the chamber might also contain small pores to allow air to escape while the 
chamber is being filled. Alternatively, if the top portion of the chamber is not inserted in fluid, 
then it might have larger air outlets.  
 
Figure 4.1  Artistic rendering of the design of the optofluidic probe and its main components. 
This includes optical fiber with attached microfluidic chamber. Sample fluid would propagate 
through the micrometer-size pores while particles are filtered out.  The bottom membrane is 
reflective, so light exiting the fiber into sample fluid contained in the chamber is coupled back 
into the same fiber for analysis. 
 
4.2.2  Fabrication Flow 
The reflective micro-porous membrane for the fluid chamber was fabricated using 
standard micro-fabrication processes (Figure 4.2) [139, 140].  Double-side polished silicon 
wafers purchased from Nova Electronic Materials (Texas) were used as the substrate (Figure 4.2 
a).  First, a 1 µm thick membrane layer of silicon nitride (Si3N4) was grown on both sides of the 
wafer by low stress–low pressure chemical vapor deposition (LPCVD) at the MiRC facility at 
Georgia Tech (Figure 4.2 b). Wafers were cleaned with acetone and IPA, then dried with 
d 
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nitrogen. Additionally, they were baked on hotplate @ 115ºC for 5 minutes to dehydrate and 
then cooled for a couple of minutes before spin-coating with photoresist. 
Next, Si3N4 layer was patterned (Figure 4.2 c), defining the transparent microfiltering 
membrane on one side and optic fiber opening on the other side. It was done by spin-coating 
positive photoresist followed by UV lithography and reactive ion etching on both sides of the 
wafer. Two consecutive photolithography steps required through-wafer alignment using IR mask 
aligner. The recipe for the photoresist deposition was the following: 4620AZ Positive Resist was 
spin-coated first at 4000rpm for 30 seconds, then at 500rpm for 10 seconds and finally at 
6500rpm for 60 seconds. This allowed to achieve the most uniform surface coverage. Then it 
was baked in oven at 100°C for 20 minutes and rehydrated for 24 hours. The exposure was 7 
seconds on Karl Suss mask aligner (lamp intensity 25 mW/cm2). After that it was developed for 
3 min in photoresist 400K developer, hard baked at 100°C for 30 minutes and used for etching in 
RIE.  
After patterning silicon nitride layers the exposed silicon was etched away in a solution 
of potassium hydroxide (KOH, 85°C) for 7 hours, creating a hollow chamber between the two 
nitride layers. This chamber will be filled with the fluid under study through the nitride 
membrane. Finally, 200 nm of gold was deposited on top of the nitride membrane using a 
Denton Thermal Evaporator.  An optical microscopy image of the micro-fabricated membrane is 
shown in Figure 4.2 f.  The circular pores of the membrane are 10 µm in diameter, and have been 
patterned in a square array with the distance of 15 µm from center to center. This configuration 
of the membrane allows for filtration of particles larger than 10 µm in diameter. 
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4.2.3  Filtration Experiment 
 Once the membranes had been prepared, their filtration capabilities were tested. The 
membranes were pre-wetted and cleaned by flushing them with acetone while switching from 
sample to sample. The membranes were positioned underneath an upright optical microscope for 
observation, where the membrane surfaces were oriented perpendicular to the microscope 
objective. They were slightly elevated, allowing for space to exist beneath them. In order to 
observe filtration with these membranes, a droplet of DI water containing naturally occurring 
contaminants (dust) was placed on top of the membrane surface. By relying on gravitational 
forces alone, the droplet of water was allowed to pass through the membrane, while 
contaminants were effectively filtered out. These effects were recorded using a microscope 
camera. After the filtration experiment was completed, the membranes were easily cleaned by 
rinsing with acetone. 
 
Figure 4.2  Device fabrication. (a) Two-side polished silicon substrate. (b) Silicon nitride is 
deposited on both sides of the wafer. (c) Silicon nitride was patterned and etched on both sides.  
(d) The membrane was released using etching in KOH solution.  (e) Gold was deposited on the 
membrane. (f) Optical microscopy image of a released membrane. 
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4.2.4  Optical Experiments 
4.2.4.1  Device Packaging 
 
Figure 4.3 Details of the packaging. a) Cleaved optical fiber inserted into fiber holder, b) 
enlarged tip of the fiber that is 125 µm in diameter. c) Optical fiber holder fixed in high precision 
XYZ-stage. d) Optical fiber above reflective gold coated membrane. e) Fully assembled device 
with an optical fiber enclosed inside of the fluid chamber and a filtering membrane connected at 
the bottom. 
 
 After testing filtering properties of the micro-filtering membranes they were assembled 
next to the optical fiber tips. For this, an 8 μm optical fiber was cleaved and inserted into an 
adjustable fiber holder (Figure 4.3a) to provide mechanical support to the otherwise flexible 
fiber. The enlarged image of the exposed fiber tip is shown in Figure 4.3b.  Following this, the 
fiber holder was inserted into a high precision XYZ-stage, and the tip was positioned ~105 µm 
from a reflective metal membrane by adjusting the dial of the optical stage (Figure 4.3c). For 
optical alignment procedures, please refer to the following section (2.4.2). In Figure 4.3d, an 
enlarged image of the fiber tip and membrane in the assembly is shown. It may be seen that 
spacing (~105 µm) exists between the fiber and the membrane, and that the membrane itself is 
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coated with gold. Finally, the entire device was fixed in place by epoxying the metal surrounding 
the membranes to a small polydimethylsiloxane (PDMS) tube. This tube was created to fit tightly 
to the optical fiber holder, and the final assembly can be seen in Figure 4.3e.  
4.2.4.2  Fiber Alignment and Positioning 
 
Figure 4.4 Fabry-Perot resonance of the set-up used in this experiment. Here the resonance 
corresponds to a separation of approximately 105 μm between the fiber and reflector. 
 
As previously stated, before the setup was fixed in place the optical fiber and membrane 
required alignment and positioning at an appropriate spacing. In order to optimize coupling, the 
optical fiber was set perpendicular to the membrane. Angular alignment of the system was 
performed by adjusting the XYZ-stage, and observing the reflected power in air. An 
approximation of fiber angle was made qualitatively through visual observation. However, for 
added precision, reflected power was recorded while the fiber angle was finely tuned. The fiber 
angle was set once the reflected power reach a maximum value. 
Following angular alignment, the fiber needed to be placed at a set spacing from the 
membrane surface. The XYZ-stage allows for vertical adjustment of the fiber. However, micron 
level precision was needed to effectively determine the spacing, and thus Fabry-Perot resonance 
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was used for high precision measurements.  The resonance was formed between the two 
reflective surfaces - the gold coated membrane and the cleaved fiber interface. The spectrum was 
recorded in air (refractive index: 1.0) and conducted using infrared light between 1400 and 1500 
nm (shown in Figure 4.4 for the desired spacing). Using the collected IR spectrum, the distance 
could be calculated using the following expression:  
𝑑 =
𝜆𝑖
2
2𝑛(𝜆𝑖+1−𝜆𝑖)
                                                  Equation 1 
where λi and λi+1 are consecutive resonance wavelengths (nm), n is the refractive index. By 
recording resonance patterns for different vertical settings of the XYZ-stage, a correlation 
between stage setting and the actual distance, determined by equation 1, was obtained. Once the 
appropriate vertical setting was found, the fiber was fixed in position and the distance was 
verified again using Fabry-Perot resonance. In Figure 4.4, we can see the Fabry-Perot resonance 
recorded for the vertical setting once the fiber was set 105 µm from the membrane. 
4.2.4.3 Absorption Spectroscopy of Cobalamin 
 In order to demonstrate that the device is capable of determining drug and its 
concentrations, absorption spectroscopy was conducted for a specific pharmaceutical– cobalamin 
(vitamin B12). Different drugs can be identified using UV-vis spectroscopy. For example, 
absorption spectrum of cobalamin dissolved in water with concentration 60 mg/dL is shown in 
Figure 4.5a. When drug is known, its concentration can be measured at one specific wavelength, 
since it is much faster than measurements of the whole spectrum. 
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a) b)  
Figure 4.5 Experimental absorption spectrum.  (a) and theoretical transmission profiles 
for Cobalamin (b) at varying concentrations and fiber spacing. 
 
 The goal was to construct a sensor that would be able to conduct measurements for the 
broad range of concentrations from 0.1 mg/dL to 500 mg/dL.  Theoretical modeling of this 
sensors transfer function was conducted using Beer-Lambert law: 
𝑃
𝑃𝑜
= 𝑒𝑥𝑝(−2𝛼𝑑𝐶)                                                 Equation 2 
where P is the power of transmitted light (W) for the fluid under study, Po is the transmitted 
power (W) for a pure sample, α is the molar absorptivity with units of L/mol∙cm, 2∙d is the total 
optical path where d was the spacing between the fiber and reflective surface (cm), and C is the 
concentration of the cobalamin expressed in mol/L. 
Figure 4.5 shows the theoretical transfer functions plotted for the needed range of 
concentrations and three different spacing between the fiber and the membrane – 75, 105 and 
150 µm.  While 150 µm gap is better for the measurements of lower concentrations, and 75 µm 
works better for higher concentrations, the 105 µm gap is suitable for both ranges and thus was 
chosen for the experimental testing. 
 During the experiment, the concentration of cobalamin was varied from approximately 
0.1 mg/dLto 515 mg/dL, while reflected power was recorded for each concentration.  All 
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measurements were conducted over 5 minute timeframes, during which the power was averaged. 
A high stability green laser (532 nm) was used at a fixed power at 30 mW.  After one cobalamin 
measurement was made, the sample was removed, and the sensor was thoroughly rinsed with 
water. This cleaning was conducted to prevent build-up of cobalamin on surfaces. After cleaning, 
the setup was allowed to air dry for approximately one minute, ensuring that all water was 
removed from the system.  Samples were tested sequentially with increasing concentration. In 
order to ensure reproducibility of results, every test was calibrated with respect to the water 
control measurements. 
4.3 Results and Discussion 
4.3.1  Filtration Demonstration 
As previously mentioned, the filtering properties of the micro-fabricated porous 
membrane were demonstrated with a drop of DI water. Figure 4.6a and 4.6b show the empty 
membrane placed horizontally under the microscope and a membrane right after putting a drop 
of water, respectively. It may be noticed that the water passes through the pores in the 
membrane, and forms a drop on the other side, while all particles are filtered by the pores and 
remain on the membrane surface (Figure 4.6b-f).  Figure 4.6f demonstrates the outline of the 
water drop that is not fully seen since it is already under the membrane, and the dark spots are 
particles that are present in all real world samples and were successfully filtered out by the 
membrane. 
For cleaning purposes the membrane was flushed with acetone. It was observed that this 
also improved its wetting properties. While without applying additional pressure, water flow 
takes several minutes to completely pass through the membrane. However, prior prewashing 
decreases this time to seconds (Figure 4.6 g-i). The membrane was also tested continuously with 
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the lowest setting of a peristaltic pump pumping fluid with the flow rate ~2µL/s, and it could 
withstand the external pressure still demonstrating successful particle filtration. 
 
Figure 4.6 Demonstration of successful filtration using microfluidic membrane. While water 
goes through the membrane for further analysis, all the contamination stays on the surface.  
 
4.3.2 Optical Measurement of Cobalamin Concentrations 
While the proposed optofluidic platform is compatible with a broad range of drugs, here 
we demonstrated measurements of cobalamin concentration as an example drug that can be 
monitored using this approach.  Cobalamin (vitamin B12) is an essential water-soluble vitamin, of 
which a deficiency can lead to abnormal neurologic and psychiatric symptoms. This may include 
ataxia (shaky movements and unsteady gait), muscle weakness, spasticity, incontinence, 
hypotension (low blood pressure), vision problems, dementia, psychoses, and mood 
disturbances. There is a variety of doses that are used for injections: from 0.2µg/kg for neonates 
and infants to 1000 µg total for adults with severe vitamin deficiency [141]. This means range of 
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concentrations from 1 µg/ml to 1000 µg/ml, therefore the Figure 4.7b shows measurements of 
concentrations between 1 µg /mL to 5 mg/mL to monitor the physiological range and potential 
overdose. 
Because cobalamin was the only compound sensed, all the measurements were conducted 
with a single wavelength, 532 nm, where cobalamin has high absorption and the sensor would 
have the highest sensitivity. In future sensing at multiple wavelengths can be used to monitor 
mixture of several drugs simultaneously.  
a) b)  
Figure 4.7 Sample of cobalamin concentrations and experimental results. a) Samples of different 
concentrations of cobalamin arranged in order of decreasing concentration. b) Corresponding 
experimental results of optical measurements of cobalamin concentration. 
 
Figure 4.7 (a) shows the solutions of cobalamin used in this experiment in order of decreasing 
concentration (left to right).  As a results, the experimental points are well fitted by the 
theoretical curve obtained using Beer-Lambert Law (R2=0.994). 
4.4 Conclusion 
In conclusion, we presented a new optofluidic platform for near-patient drug monitoring 
designed with the purpose of providing additional level of safety for drug administration and 
decreased human error.  This has the potential of reducing preventable deaths due to medical 
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errors.  By combining spectroscopic analysis with microfluidic filtration, the system allows rapid 
and accurate testing for drug concentrations levels.  Design, optimization, fabrication and 
experimental testing of this system for the measurement of cobalamin concentration 
demonstrated that this approach is promising.  Furthermore, it opens up a whole area of 
optofluidic fiber based drug monitoring where future work includes analysis of multiple drugs 
and their mixtures and integration with syringes and IV-bags. 
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CHAPTER 5:  DESIGN OF AN OPTOFLUIDIC SENSOR FOR RAPID DETECTION OF 
HEMOLYSIS 
 
5.1 Introduction 
 Every day millions of blood samples are collected in hospitals and clinics for analysis, 
and a significant portion of those samples are compromised due to hemolysis: up to 31% for 
blood drawn in emergency rooms and 10% in blood banks and blood testing facilities [19, 142]. 
Significant effort has been devoted to reducing the rate of hemolysis in blood samples by 
optimizing collection techniques, through the use of appropriate needles and other methods; 
however, no significant improvement has been demonstrated [4]. Additionally, there are many 
causes of later hemolysis of a correctly collected blood sample, such as improper sample 
collection, handling, transportation, and storage [4, 24] . 
 This high rate of blood sample compromise negatively influences several aspects of the 
healthcare system and has a pronounced adverse economic impact. Millions of dollars are wasted 
each year because instruments for prompt, low-cost hemolysis detection are not available. 
Diagnoses are delayed, and some tests produce erroneous results, evidence to the fact that 
hemolysis is the leading cause of pre-analytical errors [24, 143]. Hemolysis interference also 
affects a number of important biochemical tests, such as lactate dehydrogenase (LD), aspartate 
aminotransferase (AST), bilirubin, cholesterol, and glucose tests.  The quality of blood test 
results can be compromised even when the level of hemolysis is undetectable by visual 
inspection (plasma hemoglobin less than 50 mg/dL) [144]. In addition to sample contamination 
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due to in vitro hemolysis, in vivo hemolysis is also a problem, resulting in vascular disease, 
inflammation, thrombosis, and renal impairment [7]. Evidence of hemolysis can be detected at 
10 mg/dL in some conditions, while grossly hemolyzed samples might have free plasma 
hemoglobin concentration of 500 mg/dL and above. 
Currently there is no reliable way to detect hemolysis without first separating the blood 
plasma from the whole blood sample. The traditional detection method is visual assessment of 
the level of “redness” of the separated plasma. This approach, however, results in a high 
percentage of human errors and miscategorizations. Alternatively, there are several automatic 
methods of free plasma hemoglobin measurement such as ELISA and spectrophotometry [145] 
[25-27]. These automatic methods of hemolysis detection are time-consuming and expensive. As 
a result, these methods do not work well for rapid assessments of sample quality. 
Here we propose a new device that allows for quantitative measurement of the level of 
hemolysis of just a drop of plasma using absorption spectroscopy. Quantitative measurements 
are available instantaneously, and the method is reagent-free. Significantly, this portable device 
can be used for quality control in blood testing facilities or in hospitals before blood transfusions.  
For the above reasons, we optimized the instrument for the range of measurements between 0 
and 500 mg/dL. 
5.2 Device Packaging and Design 
 Detection of hemolysis requires that measurements be made of free plasma hemoglobin. 
It cannot be done in whole blood samples because of interference from unlysed blood cells. 
Thus, the cells must first be separated from the sample before the plasma can be analyzed. This 
can be achieved by centrifugation and then using an optical fiber platform and absorption 
spectroscopy techniques to measure hemoglobin concentration. Figure 5.1a shows the proposed 
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design, while Figure 5.1b shows the assembled prototype. Here the whole structure is inserted 
into a molded PDMS tube with a thin capillay. A cleaved optical fiber can be fixed in a fiber 
holder that can be moved freely within filtered plasma.  The PDMS forms an airtight seal with 
the fiber capillary holding the fiber holder and fiber.  
 
Figure 5.1 Proposed design for the spectroscopic probe. a) Proposed design for the spectroscopic 
probe. b) Fully assembled spectroscopic probe, including optical fiber, PDMS holder, and 
reflective membrane. 
 
 A thin (~1 µm) reflective porous membrane is attached at the bottom of the chamber. The 
reflective membrane is fabricated using a conventional photolithographic process with gold 
deposition, as described in a previous work [28]. Specifically, silicon nitride was deposited on a 
double-side silicon wafer, and positive resist was used for design patterning. After 
photolithography, nitride etching and wet-etching for silicon layer, 200 nm of gold was deposited 
on the silicon nitride membrane. The supporting wafer was attached using epoxy to ensure a 
watertight seal.  Pores (1–3 µm in diameter) were etched across the whole membrane in a square 
array. The entire device, fully assembled for experimental use, is shown in Figure5.1b.  
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A drop of plasma can be applied on the surface of the membrane that, through capillary action, 
moves into the miniature chamber and inserted capillary. The plasma can subsequently  be 
analyzed. Spectroscopic analysis of plasma is performed to measure the concentration of free 
hemoglobin. Light from the optical fiber passes through the fluid, eventually reaching the 
reflective gold coated membrane. The reflected light is couple back to the optical fiber into the 
power meter for measurement. The whole device can be inserted into acetone for a quick flush, 
as an easy cleaning technique.   
5.3 Optimization of Optical Parameters 
Hemolysis is detected by measuring the concentration of hemoglobin in the plasma. Light 
absorption is measured with a single optical fiber (Figure 5.1a), and then the Beer-Lambert law 
is applied. The Beer-Lambert equation relates light transmission to the concentration of optically 
absorptive compounds in a sample.: 
                                                                   𝑇ℓ = exp(−2𝛼ℓ𝐶)                                          Equation 1 
where ℓ is the spacing distance between the tip of the optical fiber and the reflective membrane 
(cm), 𝐶 is the concentration of hemoglobin in the plasma (mol/L), 𝛼 is the wavelength-dependent 
molar absorptivity of hemoglobin (L/mol∙cm), and 𝑇ℓ is the resulting fraction of light transmitted 
through the sample at the set spacing ℓ. 
 Hemoglobin is found naturally in two variations (oxygenated and deoxygenated), which 
must be taken into consideration. Both variations of hemoglobin have own distinct values of 
molar absorptivity (𝛼) at different parts of the electromagnetic spectrum. However, for a few 
wavelengths of light (isosbestic points), 𝛼 for oxygenated and deoxygenated hemoglobin is the 
same. Over the wavelength range from 500 to 600 nm, four isosbestic points occur, at 
approximately 530, 545, 570, and 584 nm, with 𝛼 values of 0.0138, 0.0188, 0.0167 and 0.0127 
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L/mol∙cm, respectively [94]. The advantage of using isobestic points is that a single wavelength 
can be used to determine the total (both forms) concentration of hemoglobin. For this method, a 
wavelength of 545 nm was selected because of the high corresponding absorption. 
 After choosing the wavelength (thus determining the molar absorptivity), there remain 
three unknown variables of the Beer-Lambert equation (eq. 1). Hemoglobin concentration (𝐶) is 
the variable we wish to determine, and transmission (𝑇ℓ) is the variable we can directly measure. 
The spacing (ℓ) can be chosen such that the sensor operates with an optimum level of 
performance.  
Figure 5.2 shows the influence of the spacing (ℓ) on the transfer function relating light 
transmission to hemoglobin concentration. Fiber spacing is chosen depending on the desired 
range of sensor measurements. For example, if expected hemoglobin concentrations can be up to 
only 100 mg/dL, then a larger fiber spacing (4.0 mm) would be chosen to achieve the best 
resolution within that range. It will allow to accumulate larger optical absorption in thicker layer 
of plasma and extract more information about low hemoglobin concentrations. If much higher 
concentrations of hemoglobin are to be measured, then a smaller spacing should be chosen. 
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Figure 5.2 Transfer functions relating normalized for different spacings (ℓ) between the fiber 
and the reflective membrane. 
 
For a sensor that displays exponential decay as its operating curve, we consider 
performance to light transmission to hemoglobin concentration, be optimal when there exists a 
strong negative decay over the concentration range of interest. This allows for distinct and well-
defined changes in transmission, as well as greater sensitivity in resolving concentration values. 
However, the performance curve must not display too steep of an exponential decay, as the 
sensor would then lose sensitivity in resolving concentrations at the extremities of the range of 
interest.  
 To characterize sensor behaviors over a range of hemoglobin concentrations, two 
operation parameters were created through manipulations of statistical curve regression analysis 
and least squares error. These parameters are the fraction of maximum decay (ψ) and the degree 
of curvature (φ). The fraction of maximum decay is a measure of how much the signal ‘decays’ 
over the range of interest (Ca to Cb). A value of zero indicates a curve with no decay, while a 
value of one implies that maximum decay has been reached over the range of interest (i.e., 
transmission at Cb is 0%). Derivation and simplification of this parameter is shown in eq. 2. 
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                          𝜓 = (
𝑇ℓ(𝐶𝑏) − 𝑇ℓ(𝐶𝑎)
𝐶𝑏 − 𝐶𝑎
) (
𝐶𝑏 − 𝐶𝑎
𝑇∞(𝐶𝑏) − 𝑇∞(𝐶𝑎)
) = 1 −
𝑇ℓ(𝐶𝑏)
100%
               Equation 2 
In Equation 2, transmission 𝑇ℓ is written as a function of concentration C, and the 
denotation ℓ signifies that the separation between the fiber and membrane is at a fixed length ℓ. 
As such, 𝑇∞ is the transmission that corresponds to a fixed separation for which the tip of the 
optical fiber and the reflective membrane are infinitely far apart. The other parameter, the degree 
of curvature φ, measures the extent to which the exponential sensor deviates from a linear 
operation behavior. A degree of curvature near one indicates that the curve is behaving 
approximately linear, and as this value decreases, the operation curve deviates from a liniar fit 
over the range of interest. This parameter was derived through modification of the least squares 
correlation coefficient, to describe the squared error between the exponential operation curve 
‘𝑇ℓ’ and a hypothetical performance curve for a linear sensor ‘𝜃ℓ.’ Expressions for φ and 𝜃ℓ are 
given below in Equation 3 and 4 respectively. 
                          𝜙 = 1 −
∫ (𝜃ℓ − 𝑇ℓ)
2𝑑𝐶
𝐶𝑏
𝐶𝑎
∫ (𝜃∞ − 𝑇∞)2𝑑𝐶
𝐶𝑏
𝐶𝑎
= 1 −
∫ (𝜃ℓ − 𝑇ℓ)
2𝑑𝐶
𝐶𝑏
𝐶𝑎
∫ (𝜃∞)2𝑑𝐶
𝐶𝑏
𝐶𝑎
                       Equation 3 
 
                                                𝜃ℓ = (
𝑇ℓ(𝐶𝑏) − 𝑇ℓ(𝐶𝑎)
𝐶𝑏 − 𝐶𝑎
) ∙ 𝐶 + 100%                              Equation 4 
 Solving Equation 1 through 4 for an effective hemoglobin concentration range from 0 to 
500 mg/dL and iterating over various spacings (ℓ), the two behavior parameters could be 
calculated (Figure 5.3a). When the spacing is near 0 mm (i.e., fiber and membrane are nearly 
touching), the sensor behaves practically linearly; however the rate of decay is significantly low. 
Conversely, at larger separation lengths, the decay rapidly reaches its maximum value; however, 
the sensor operates exponentially. By multiplying the two parameters (φψ), the optimum 
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behavior can be determined by locating the relative maximum value, which in turn reveals the 
optimal spacing required to achieve this desired behavior. Figure 5.3b shows the results of this 
multiplication, with a maximum value at approximately 1.27 mm. 
Figure 5.4 shows the theoretical transfer function for the proposed hemolysis sensor 
based on solving the Beer-Lambert law (eq. 1) for the optimal spacing.  Knowing the optimum 
chamber length, this operating curve for the sensor can be achieved.  This indicate that 
transmission drop between a pure plasma (0 mg/dL of hemoglobin) to a slightly hemolyzed 
sample of (30 mg/dL) is approximately 13% change.  
 
 
Figure 5.3 Sensor parameter optimization based on optical detection of hemoglobin over the 
concentration range 0–500 mg/dL. a) Parameters describing sensor behavior are shown for 
various chamber lengths, ℓ. b) Multiplying these two parameters, a spacing for optimum optical 
performance can be found. 
 
a b 
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Figure 5.4 Theoretical performance curve for the optimum sensor configuration over normalized 
transmission measurement of wide range of hemoglobin concentration measured in milligrams 
per deciliter (mg/dL). 
 
5.4 Experimental Detection of Hemoglobin 
 Measuring the distance between the gold-coated membrane and the optical fiber is crucial 
for determining the exact concentration of hemoglobin in a plasma sample.  Therefore, a 200 μm 
cleaved optical fiber was inserted into a fiber holder, which was then connected to an XYZ-stage 
and adjusted to a distance of about 1025 µm from the gold surface.  The system was optically 
aligned by adjusting the XYZ-stage and observing the reflected power when the chamber was 
filled with either air or water. The recorded Fabry-Perot resonance formed between the cleaved 
fiber and the gold surface was used to determine the precise distance and to adjust it to the 
needed value [146]. Figure 5.5 shows theoretical and experimental analysis of the percentage of 
light lost due to diffraction for different optical fibers. It can be noticed that for the propagation 
lengths we are interested in, optical fiber with 200 µm core diameter loses the lowest amount of 
light.  
 Serial concentration solutions of hemoglobin were then prepared in blood plasma using 
animal plasma and hemoglobin from bovine blood lyophilized powder. The reflection 
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measurements were taken over a large range of concentrations (0–500 mg/dL). Each set of 
measurements was repeated three times over duration of 5 minutes for each concentration of 
hemoglobin. All the measurements were normalized relative to the initial laser power. The 
results can be seen in Figure 5.6, a plot of the averaged power vs. hemoglobin concentration.    
 
 
 
Figure 5.5 Left: Percentage of light lost due to diffraction for 8, 50 and 200 μm core optical 
fiber. Right: Losses were measured for the chamber filled either with air (red) or water (blue), 
and model curves were fit to the experimental data. 
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Figure 5.6 Experimental results showing decrease of reflected light with increase of hemoglobin 
concentration. The data points show exponential decay due to increased absorption together with 
periodic fluctuations because of the change of refractive index in the Fabry-Perot resonator. 
 
5.5 Conclusions 
 A method for rapidly detecting hemolysis, using only microliters of plasma, has many 
critical applications for blood-testing quality control and safety control. In this work, we 
proposed, theoretically optimized, fabricated, and tested miniature instrument to rapid test for 
hemolysis in plasma samples for a broad range of hemoglobin concentrations. This sensing 
platform integrates the optical fiber technology and the microfluidic reflective membrane.   
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CHAPTER 6:  CONCLUSIONS AND FUTURE WORK 
 
The negative impact of hemolysis has significantly affected healthcare as well as national 
and global economy.  To address these worldwide health concerns, we specifically focused on 
hemolysis in maternal complications. A novel biomedical platform, optofluidic device was 
investigated for point-of-care clinical and analytical assessment of hemolysis for implementation 
in low resource settings and the developing world.  A combinatory approach was taken by 
integrating optics and microfluidics.  As a result, a new device was introduced with successful 
fabrication of the 3-dimentional microfilter.  The proposed microfilter would enable a new 
direction in the field of microfluidics analysis.  This system will be useful not only toward this 
research, but in any microfiltering system, where spectroscopic analysis is needed real-time.  The 
developed platform can be applied for affordable, rapid and accurate testing in other areas such 
as protein level quantification, and diseases such as sickle-cell.   
In addition to the microfilters, a mobile platform was designed to accurately quantify 
hemolysis by assessing the levels of hemoglobin through color analysis.  Results of this work 
showed successful detection of critical levels of hemoglobin due to hemolysis without any 
sample pre-processing.  This achievement was to target preeclampsia and HELLP syndrome 
rapidly, near-patient, especially in developing countries.  An international patent was filed during 
this project and clinical assessments will be continued toward improving the device and mobile 
platform.  
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